Schizophrenia Clinical Trials in Los Angeles

Showing 61-80 of 166 trials

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

NCT03883360

A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of Δ9-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.

Schizophrenia Spectrum DisordersCannabis Use

University of Maryland, BaltimoreStarted Jan 2050

Los Angeles, California, United States • Baltimore, Maryland, United States • Catonsville, Maryland, United States

COMPLETEDPhase 36.3 miles

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Schizophrenia

Alkermes, Inc.266 participantsStarted Aug 2016

Little Rock, Arkansas, United States • Springdale, Arkansas, United States • Anaheim, California, United States +42 more locations

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Schizophrenia Trials in Other Cities

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

A Study of ALKS 3831 in Adults With Schizophrenia

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

An Integrated Program for the Treatment of First Episode of Psychosis

Comparative Bioavailability of Risperidone

Study of CAD-9303 in Subjects With Schizophrenia

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Comparative Bioavailability of Risperidone.

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Bio-equivalence Study Between SAPHRIS and Asenapine

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Other Conditions in Los Angeles